Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Capital Expenditure : ¥-429.19 Mil (TTM As of Mar. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Nanjing King-Friend Biochemical Pharmaceutical Co Capital Expenditure?

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Nanjing King-Friend Biochemical Pharmaceutical Co's cash flow for capital expenditures for the three months ended in Mar. 2024 was ¥-50 Mil. Its cash flow for capital expenditures for the trailing twelve months (TTM) ended in Mar. 2024 was ¥-429.19 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co Capital Expenditure Historical Data

The historical data trend for Nanjing King-Friend Biochemical Pharmaceutical Co's Capital Expenditure can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Nanjing King-Friend Biochemical Pharmaceutical Co Capital Expenditure Chart

Nanjing King-Friend Biochemical Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Capital Expenditure

Get a 7-Day Free Trial

-115.41

-294.36

-440.76

-470.08

-419.07

Nanjing King-Friend Biochemical Pharmaceutical Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Capital Expenditure	Get a 7-Day Free Trial															-39.43	-46.23	-107.55	-225.87	-49.55

Nanjing King-Friend Biochemical Pharmaceutical Co Capital Expenditure Calculation

Cash flow for capital expenditures refers to the funds spent for a company to acquire or upgrade physical assets such as property, industrial buildings or equipment.

Capital Expenditure for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥-429.19 Mil.

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Nanjing King-Friend Biochemical Pharmaceutical Co Ltd (SHSE:603707) » Definitions » Capital Expenditure

Traded in Other Exchanges

N/A

Address

1/16 Xuefu Road, Nanjing High-Tech Zone, Nanjing, CHN, 210061

Website

http://www.nkf-pharma.com

Nanjing King-Friend Biochemical Pharmaceutical Co Ltd is a China-based company engaged in the research and development, import and export of medicines and health products. The main products of the company are Heparin sodium and low molecular weight heparin. Geographically, the business activities are carried out through China and it exports the product mainly to the European and American countries.

Executives

Huang Xi Wei	Director
Liu Zu Qing	Supervisors
Xie Ju Hua	Director
Wu Gui Ping	senior management
Tang Yong Qun	Director
Qian Xiao Jie	senior management

Nanjing King-Friend Biochemical Pharmaceutical Co (SHSE:603707) Headlines

No Headlines